ArticleAging2019
Real-world effectiveness of medications on survival in patients with COPD-heart failure overlap.
Article in Aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Could patients with chronic obstructive pulmonary disease benefit from renin angiotensin system inhibitors? A meta-analysis.BMJ open respiratory research · 2023Pooled it
- Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison.Respiratory research · 2021Pooled it
- Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy.Life (Basel, Switzerland) · 2023Review
- Influence of chronic obstructive pulmonary disease on long-term hospitalization and mortality in patients with heart failure with reduced ejection fraction.BMC pulmonary medicine · 2023Article
- Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences.Therapeutic advances in chronic disease · 2023Review
- Cardiovascular Medication Use and Risk of Acute Exacerbation in Patients With Asthma-COPD Overlap (CVACO Study).Allergy, asthma & immunology research · 2022Article
- Analysis of pathogenesis and drug treatment of chronic obstructive pulmonary disease complicated with cardiovascular disease.Frontiers in medicine · 2022Review
- Association of primary Sjögren's syndrome with incident heart failure: a secondary analysis of health claims data in Taiwan.Therapeutic advances in chronic disease · 2022Article
- Relationships Between Bronchodilators, Steroids, Antiarrhythmic Drugs, Antidepressants, and Benzodiazepines and Heart Disease and Ischemic Stroke in Patients With Predominant Bronchiectasis and Asthma.Frontiers in cardiovascular medicine · 2022Article
- Cardiovascular outcomes of metformin use in patients with type 2 diabetes and chronic obstructive pulmonary disease.Frontiers in pharmacology · 2022Article
- Dynamic Trajectory of a Patient-Reported Outcome and Its Associated Factors for Patients with Chronic Heart Failure: A Growth Mixture Model Approach.Risk management and healthcare policy · 2022Article
- Population-based retrospective cohort study on risk of age-related macular degeneration in people with chronic obstructive pulmonary disease.Scientific reports · 2021Article
- Thiazolidinedione Use in Individuals With Type 2 Diabetes and Chronic Obstructive Pulmonary Disease.Frontiers in medicine · 2021Article
- Enhanced risk of traumatic brain injury in patients with chronic obstructive pulmonary disease.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2020Article
- Article
- Trends and Changes in Intensive Care Use for Patients With Heart Failure in the Last Month of Life.Inquiry : a journal of medical care organization, provision and financingObservational
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The appropriate treatment for patients with coexistent chronic obstructive pulmonary disease (COPD) and heart failure (HF) remains unclear. Data from the Taiwan National Health Insurance Research Database was used for this retrospective cohort study. Patients diagnosed with both diseases between 1997 and 2012 were enrolled as the COPD-heart failure overlap cohort. Patients were categorized as non-users and users of specific COPD and HF medications. Medication prescriptions in each 3-month and 1-year period served as time-dependent covariates. The primary endpoint was cumulative survival. The validation study confirmed the accuracy of definitions of COPD (94.0% sensitivity) and HF (96.3% sensitivity).The study included 275,436 patients with COPD-heart failure overlap, with a mean follow-up period of 9.32 years. The COPD-heart failure overlap cohort had more medical service use and higher mortality than did the COPD alone cohort. Use of inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) combinations, long-acting muscarinic antagonist (LAMA), angiotensin receptor blockers (ARBs), β blockers, aldosterone antagonists, and statins reduced mortality risk compared with non-use. Sensitivity and subgroup analyses confirmed the consistency and robustness of results.ICS/LABA combinations, LAMA, ARBs, β blockers, aldosterone antagonists, and statins use was associated with a lower mortality risk in patients with COPD-heart failure overlap.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.